موافقات الدواء

Indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
Dapagliflozin is indicated to reduce:
• The risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. • The risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction. • The risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
Dezeroga-Met® is not recommended:
• For patients with type 1 diabetes mellitus or diabetic ketoacidosis. • Because of the metformin component, the use of Dezeroga-Met® is limited to adults with type 2 diabetes mellitus for all indications.
• For the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. Dezeroga-Met® is not expected to be effective in these populations.